Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China FDA Proposes New Rules to Speed Foreign Drug Approvals

publication date: Mar 20, 2017
China's FDA is circulating a draft proposal that would speed up China approval of novel foreign drugs. Under the new rules, if a drug's IND is already approved in another country, it would be exempted from filing a China IND/CTA request before starting China clinical trials. The change has important implications for multinational global trials. The new rules would allow a pharma to implement a China arm of a global trial without waiting for the CFDA to approve an IND/CTA. Because IND/CTA approvals can take as long as two years in China, China was often not included in global trials, as pharmas could not afford to put large, important trials on hold while they waited for the CFDA to issue an IND/CTA ruling. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital